GTC Biotherapeutics (fka GTCB)

[ThomasS]

Dew, the inherent problem remains one of perception for the average patient, not for investors/academics/astute followers of technology such as yourself.
John Q Public would rather receive a "safe" plasma derivative, than one from a goat. imo, at least 90% of the time.
We would take the goat product without reservation, but, we have extensive exposure to an issue that the public does not. Of course, left solely in Practitioners hands, that percentage would likely decrease to 20%.